Achillion Pharmaceuticals (ACHN) Upgraded to “Sell” at BidaskClub

BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a strong sell rating to a sell rating in a report published on Monday, February 5th.

A number of other research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 price objective on the stock in a research note on Monday, November 6th. Leerink Swann restated a buy rating and issued a $5.00 price objective on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $4.89.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) opened at $2.98 on Monday. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The company has a market cap of $410.82, a price-to-earnings ratio of -6.08 and a beta of 1.32.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction on Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 7.24% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACHN. Schwab Charles Investment Management Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock valued at $2,100,000 after acquiring an additional 2,850 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Achillion Pharmaceuticals by 1.8% in the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 3,827 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of Achillion Pharmaceuticals by 13.7% in the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 6,730 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its holdings in shares of Achillion Pharmaceuticals by 15.2% in the second quarter. Nationwide Fund Advisors now owns 93,443 shares of the biopharmaceutical company’s stock valued at $429,000 after acquiring an additional 12,303 shares in the last quarter. Institutional investors own 76.81% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/achillion-pharmaceuticals-achn-stock-rating-upgraded-by-bidaskclub.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply